Activity of posaconazole in treatment of experimental disseminated zygomycosis.
Three isolates of zygomycetes were used to produce a disseminated infection in nonimmunocompromised mice. Against all zygomycete strains, amphotericin B significantly prolonged survival. Itraconazole was inactive against Rhizopus microsporus and Rhizopus oryzae but was partially active against Absidia corymbifera. Posaconazole had no beneficial effects against R. oryzae but showed partial activity against A. corymbifera. Posaconazole had a clear dose-response effect against R. microsporus.
Dannaoui
Eric
E
Department of Medical Microbiology, University Medical Center, St. Radboud, 6500 HB Nijmegen, The Netherlands. dannaoui@pasteur.fr
Meis
Jacques F G M
JF
Loebenberg
David
D
Verweij
Paul E
PE
D020095:Absidia / Q000187:drug effects; D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001921:Brain / Q000382:microbiology; D005260:Female; D017964:Itraconazole / Q000494:pharmacology / Q000627:therapeutic use; D007668:Kidney / Q000382:microbiology; D051379:Mice; D008826:Microbial Sensitivity Tests; D012233:Rhizopus / Q000187:drug effects; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D020096:Zygomycosis / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents; D014230:Triazoles; D017964:Itraconazole; C101425:posaconazole; D000666:Amphotericin B